Published in TB and Outbreaks Week, October 2nd, 1995
As a result of these trials large-scale efficacy studies are underway in the Republic of South Africa and the United Kingdom.
Researcher J.L. Stanford and colleagues presented the results of preliminary animal and human trials of SRL 172 at The Lancet Conference 1995, "The Challenge of Tuberculosis," held in Washington D.C., September 14 and 15, 1995.
SRL 172 is a suspension of heat-killed Mycobacterium vaccae, NCTC 11659, 0.1 ml of which contains 1...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week